by
John R. Fischer, Senior Reporter | March 04, 2024
Progenics says that MIM Software stole its patented technology to enhance its solutions and try to attract GE HealthCare into acquiring it.
Progenics Pharmaceuticals, a biopharmaceutical company, has accused radiology AI solution maker MIM Software of using its patented technology to secure an acquisition from GE HealthCare.
In documents filed in the U.S. District Court for the District of Massachusetts, Progenics said that for years it discussed with MIM the possibility of integrating patents for new systems and methods to help physicians more consistently and accurately interpret CT and PET scans into MIM’s nuclear imaging software through a partnership.
It said it sent MIM a collaboration agreement in October 2022 but did not hear back for months, only to discover in June 2023 that MIM had published articles and information on its website about new features added to its Contour ProtégéAI and MIM SurePlan MRT solutions that were similar to Progenics’ patented technology. It also accused MIM of using these features to make itself more attractive to GE HealthCare, which
announced in January its intention to acquire the company and has not yet completed the deal.
“Upon information and belief, MIM disregarded the asserted patents after deciding that it was simply more convenient than paying for a license to use them,” said Progenics in its complaint.
Progenics, which was acquired in 2020 by Lanteus and develops AI along with targeted pharmaceuticals to identify and attack cancer, is asking the court to issue a judgment that MIM stole its patents and for the company to pay it monetary damages. It also is seeking a court order to protect against further infringement.
MIM, which is based in Cleveland, sells imaging tools for radiation oncology, radiology, nuclear medicine, neuro, cardiology, and urology solutions. It designs vendor-agnostic software that integrates diagnostic images from multiple modalities into treatment plans.
GE HealthCare plans to integrate MIM’s technology with its advanced visualization solutions to add AI-based segmentation and contouring as well as dosimetry analysis to make clinicians better able to precisely evaluate patients throughout their treatment.
MIM did not respond for comment. GE HealthCare told HCB News that it does not comment on pending litigation.
